Evidence-Based Guidelines for Empirical Therapy of Neutropenic Fever in Korea
Open Access
- 1 January 2011
- journal article
- practice guideline
- Published by Korean Association of Internal Medicine in The Korean Journal of Internal Medicine
- Vol. 26 (2), 220-252
- https://doi.org/10.3904/kjim.2011.26.2.220
Abstract
Neutrophils play an important role in immunological function. Neutropenic patients are vulnerable to infection, and except fever is present, inflammatory reactions are scarce in many cases. Additionally, because infections can worsen rapidly, early evaluation and treatments are especially important in febrile neutropenic patients. In cases in which febrile neutropenia is anticipated due to anticancer chemotherapy, antibiotic prophylaxis can be used, based on the risk of infection. Antifungal prophylaxis may also be considered if long-term neutropenia or mucosal damage is expected. When fever is observed in patients suspected to have neutropenia, an adequate physical examination and blood and sputum cultures should be performed. Initial antibiotics should be chosen by considering the risk of complications following the infection; if the risk is low, oral antibiotics can be used. For initial intravenous antibiotics, monotherapy with a broad-spectrum antibiotic or combination therapy with two antibiotics is recommended. At 3-5 days after beginning the initial antibiotic therapy, the condition of the patient is assessed again to determine whether the fever has subsided or symptoms have worsened. If the patient's condition has improved, intravenous antibiotics can be replaced with oral antibiotics; if the condition has deteriorated, a change of antibiotics or addition of antifungal agents should be considered. If the causative microorganism is identified, initial antimicrobial or antifungal agents should be changed accordingly. When the cause is not detected, the initial agents should continue to be used until the neutrophil count recovers.Keywords
This publication has 176 references indexed in Scilit:
- Antiviral prophylaxis in haematological patients: Systematic review and meta-analysisEuropean Journal of Cancer, 2009
- Oral moxifloxacin for outpatient treatment of low-risk, febrile neutropenic patientsSupportive Care in Cancer, 2009
- Revised Definitions of Invasive Fungal Disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus GroupClinical Infectious Diseases, 2008
- A Randomized, Open-Label, Multicenter Comparative Study of the Efficacy and Safety of Piperacillin-Tazobactam and Cefepime for the Empirical Treatment of Febrile Neutropenic Episodes in Patients with Hematologic MalignanciesClinical Infectious Diseases, 2006
- Caspofungin versus Liposomal Amphotericin B for Empirical Antifungal Therapy in Patients with Persistent Fever and NeutropeniaThe New England Journal of Medicine, 2004
- High Rates of Pneumocystis carinii Pneumonia in Allogeneic Blood and Marrow Transplant Recipients Receiving Dapsone ProphylaxisClinical Infectious Diseases, 1999
- A double-blind comparison of fluconazole and nystatin in the prevention of candidiasis in patients with leukaemiaEuropean Journal of Cancer, 1999
- A Controlled Trial of Fluconazole to Prevent Fungal Infections in Patients Undergoing Bone Marrow TransplantationThe New England Journal of Medicine, 1992
- Successful Intermittent Chemoprophylaxis forPneumocystis cariniiPneumonitisThe New England Journal of Medicine, 1987
- A Randomized Trial Comparing Ceftazidime Alone with Combination Antibiotic Therapy in Cancer Patients with Fever and NeutropeniaThe New England Journal of Medicine, 1986